SAB Biotherapeutics Inc (SABSW)

Form 8-K - Current report

Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes

MIAMI, July 07, 2026 (GLOBE NEWSWIRE) -- Breakthrough T1D, the leading global type 1 diabetes (T1D) research...

Form 8-K - Current report

SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

MIAMI, May 29, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be...

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage...

Form 8-K - Current report

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

All 4 T1D participants receiving SAB-142 showed C-peptide preservation with 3 of the 4 participants showing a...

SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress

MIAMI, April 15, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]